Arrowhead Pharmaceuticals: Recent Developments and Upcoming Webinar

Arrowhead Pharmaceuticals Discontinues Cardiovascular Candidate, Focuses on Obesity and Metabolism

A month after discontinuing its Phase II cardiovascular candidate, Arrowhead Pharmaceuticals has shifted its focus towards obesity and metabolism.

Upcoming Obesity and Metabolism Webinar

The company will host a webinar on obesity and metabolism today, August 14, 2024, at 2:00 PM ET, as part of its research and development efforts.

Positive Preclinical Results for ARO-INHBE

Arrowhead Pharmaceuticals has announced positive preclinical data for ARO-INHBE, a potential treatment for non-alcoholic steatohepatitis (NASH).

Key Findings from Preclinical Studies

• ARO-INHBE significantly reduced hepatic inflammation in animal models.
• The compound improved liver function and reduced fibrosis.
• ARO-INHBE demonstrated a favorable safety profile.

These findings suggest that ARO-INHBE has the potential to be an effective treatment for NASH, a serious liver disease that can lead to cirrhosis and liver failure.

Company Overview

Arrowhead Pharmaceuticals is a Pasadena, California-based company focused on developing RNA interference (RNAi) therapeutics. RNAi is a natural process that regulates gene expression, and Arrowhead's technology allows scientists to harness this process to develop new treatments for a wide range of diseases.